CAS No.
[186692-46-6(Unlabeled)]
Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
(R)-2-((6-(benzylamino)-9-(isopropyl-d7)-9H-purin-2-yl)amino)butan-1-ol
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Seliciclib-d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Seliciclib-d7 usage and description
Seliciclib-D7 is a deuterated version of the drug Seliciclib, which is a cyclin-dependent kinase (CDK) inhibitor used in cancer therapy. CDKs are enzymes that regulate the cell cycle and their overexpression or malfunctioning can cause uncontrolled cell division leading to cancer. Seliciclib-D7 is a potent inhibitor of CDK2, CDK7, and CDK9, which are important targets in cancer treatment. It acts by binding to the ATP-binding site of these CDKs, thereby preventing their activity and halting the cell cycle progression.
The deuterated form of Seliciclib-D7 is used in pharmacokinetic studies to determine the drug's metabolic fate, bioavailability and elimination rates. Deuterium is an isotope of hydrogen that has an additional neutron in its nucleus. The use of deuterium in drug development enables the creation of drugs that have enhanced stability, longer half-lives, and reduced toxicity. In the case of Seliciclib-D7, the deuterium labeled compound is used in drug metabolism studies to track the drug's metabolic products and their excretion rates.
Seliciclib-D7 has been studied in pre-clinical and clinical trials for its potential as an anti-tumor agent. The drug has shown promising results in inducing cell cycle arrest and apoptosis in various cancer cell lines. However, further research is needed to determine its efficacy and safety in treating different types of cancer. Seliciclib-D7 is a valuable tool in drug development and cancer research, providing insights into the mechanisms of CDK inhibition and drug metabolism.
